藥明巨諾-B:2023年度報告
Pharmaceutical Juno-B (02126) issued approximately 1.231 million shares under the share award scheme
Pharmaceutical Juno-B (02126) announced that on April 2, 2024, approximately 120 will be issued under the share award scheme...
JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023
JW (Cayman) Therapeutics (HKG:2126) recorded a narrower attributable loss for the year ended Dec. 31, 2023, of 768 million yuan from 846.1 million yuan during the year-ago period, a Tuesday filing on
Read the 2023 results of Mingjuno-B (02126): Revenue increased 19.3% year-on-year, gross sales margin increased to 50.7%
On March 20, Pharmaceutical Juno-B (02126) announced its annual results for the year ended December 31, 2023.
JW THERAP-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND CHANGE IN USE OF NET PROCEEDS FROM LISTING
Pharmaceutical Juno-B (02126.HK) held a board meeting on March 20 to consider and approve annual results
Gelonghui, March 8, 丨 Pharmaceutical Juno-B (02126.HK) announced that the company would like to hold a board meeting on March 20, 2024 (Wednesday) to (i) consider and approve the Group's audited consolidated results for the year ended 31 December 2023 and their release; (ii) the proposed final dividend (if any); and (iii) address any other matters.
Gelonghui Announcements Selected (Hong Kong Stocks) | Honghai Hi-Tech Resources (00065.HK) Plans to Invest in Copper Mines in Laos
[Today's Focus] Honghai Hi-Tech Resources (00065.HK) announced that it intends to invest in the Lao copper mine, Honghai Hi-Tech Resources (00065.HK). On January 4, 2024, Hongyuan (a direct wholly-owned subsidiary of the company), the target company Laos Taishan Jiujiu Investment & Trade Co., Ltd. and the target company shareholders (including guarantors) signed the memorandum on the proposed investment in the target company's shares. According to the memorandum, during the exclusivity period, the target company shall not (and require its agents and advisors not to) directly or indirectly discuss the sale or transfer of any of the target company's shares or significant assets and copper mines with any third party
JW (Cayman) Therapeutics Signs Collaboration Deal for Development of Autoimmune Disease Treatment
JW (Cayman) Therapeutics (HKG:2126) signed an exclusive collaboration agreement with Nasdaq-listed 2seventy bio to codevelop and commercialize an autoimmune disease cell therapy product in China, a Tu
GLONGHUI ANNOUNCEMENT SELECTION (HK Stocks) | Alibaba-SW (09988.HK) to buy back a total of 897.9 million shares of common stock for USD 9.5 billion in 2023
[Today's Focus] Alibaba-SW (09988.HK) announced that it will repurchase a total of 897.9 million shares of common stock at US$9.5 billion in 2023. In the 12-month period ending December 31, 2023, the company has repurchased a total of 897.9 million common shares (equivalent to 112 million American Depositary Shares) at a total price of US$9.5 billion, including a total of 292.7 million American Depositary Shares for the quarter ended December 31, 2023. These repurchases are based on the company's share repurchase program in the US market and incense
JW (Cayman) Therapeutics: Xin Fu Has Resigned as CFO
JW (Cayman) Therapeutics: Xin Fu Has Resigned as CFO
Changes in Hong Kong stocks | Pharmacology was higher in early trading, multiple stocks rose more than 4%, Pharmacology Biotech plans to buy back H shares for no more than US$600 million
Pharmacology was higher in early trading. As of press release, Pharmacology Juno-B (02126) rose 4.7% to HK$3.12; Pharmacology Biotech (02269) rose 5.27% to HK$31.95; Pharmacology Allied (02268) rose 4.37% to HK$28.65; and Pharmacology Kant (02359) rose 82.95 HK$82.95.
Huachuang Securities: CAR-T treatment brings cure to SLE, Chinese pharmaceutical companies are expected to lead
According to a research report released by Huacheng Securities, CAR-T treatment has brought healing light to SLE. Chinese pharmaceutical companies are deeply involved in this field and are likely to be the first to read positive data and gain a leading edge. It is recommended to focus on companies with rapid clinical progress: Pharmacomin Junuo (02126), Genxi Biotech, etc.
Changes in Hong Kong stocks | Pharmacology Juno-B (02126) is now up more than 6%, the cell therapy track continues to progress, and the market size is expected to grow rapidly
Pharmaceuticals Juno-B (02126) is now up more than 6%. As of press release, it is up 6.3% to HK$2.7, with a turnover of HK$2,443,900.
Changes in Hong Kong stocks | Pharmacology Juno-B (02126) rose more than 9%, and CAR-T products were approved, and listed company Rickie Orense participated in health insurance negotiations
Pharmaceutical Juno-B (02126) rose more than 9% in early trading. As of press release, it rose 5.61% to HK$3.01, with a turnover of HK$4,2191,000.
Changes in Hong Kong stocks | Pharmaceutical Juno-B (02126) rose more than 19% in the afternoon, Rickie Orense participated in health insurance negotiations, and institutions participating in health insurance negotiations are optimistic about the market p
Pharmaceutical Juno-B (02126) rose more than 19% in the afternoon, and the recent cumulative increase has exceeded 50%. As of press release, it increased by 14.92% to HK$2.85, with a turnover of HK$4.892,800.
Changes in Hong Kong stocks | Lepu Biotech (02157) rose more than 9%, leading innovative drug concept, innovative drug price protection mechanism is expected to be implemented
The innovative drug concept continues its recent gains. As of press release, Lepu Bio-B (02157) rose 7.23% to HK$4.45; Pharmacology Juno-B (02126) rose 5.98% to HK$2.48; Clover Bio-B (02197) rose 5.63% to HK$0.75; and Genting Xinyao B (01952) rose 3.99% to HK$30.
JW THERAP-B: 2023 INTERIM REPORT
JW (Cayman) Therapeutics to Expand Strategic Alliance With Cell and Gene Therapy Firm
JW (Cayman) Therapeutics' (HKG:2126) is planning on expanding its strategic alliance with 2seventy bio, according to a Tuesday filing. The parties, which formed a partnership in 2022, intend to co-dev
2seventy Bio Cutting 176 Jobs, Search for New Chief Executive
2seventy bio Inc. stock (TSVT) rose 2.7% in premarket trading on Tuesday after the T-cell drug company for cancer treatment said it's cutting 176 jobs or 40% of its work force and launching a search f
JW Therapeutics' H1 Attributable Loss Narrows on Higher Revenue
JW (Cayman) Therapeutics' (HKG:2126) attributable loss narrowed to 380.4 million yuan, or 0.93 yuan per share, in the first half, from 429.3 million yuan, or 1.05 yuan per share, in the year-ago perio
No Data